Ipsen S.A., a biopharmaceutical company, engages in the research, development, manufacture, and sale of pharmaceutical products worldwide. It offers pharmaceutical products targeting the oncology, endocrinology, neurology, hematology, and primary care areas. Its product portfolio comprises Decapeptyl, a peptide formulation for injection to treat advanced prostate cancer; Dysport, a botulinum neurotoxin type A complex to treat spasticity of upper limbs following a stroke, as well as spasticity of other muscles; Apokyn for the treatment of off episodes associated with advanced Parkinsons disease; Smecta, a natural clay-based drug for chronic and acute diarrhoea; and Forlax for the treatment of constipation. The companys products also consist of Tanakan, an oral formulation of EGb 761 to treat age-related cognitive disorders; Nisis and Nisisco, which are oral formulations that contain valsartan for the treatment of hypertension; and Ginkor Fort, an oral formulation for the treatment of venous insufficiency of the lower limbs and acute haemorrhoid episodes. In addition, it offers Somatuline and Somatuline Autogel, which are sustained release formulations for injection of a somatostatin analogue peptide for the treatment of acromegaly and neuroendocrine tumors; and NutropinAq, a liquid formulation for the treatment of growth failure in children and growth hormone deficiency in adults.
